Two single-arm, phase II studies (NP28673, global [NCT01801111] [11] and NP28761, North American [NCT01871805] [12]) demonstrated robust efficacy and an acceptable safety profile for alectinib 600 mg twice daily (BID) in patients with ALK-positive NSCLC following crizotinib failure. Here, ALK is linked to non-small cell lung carcinoma.